Fatty acid synthase is a metabolic marker of cell proliferation rather than malignancy in ovarian cancer and its precursor cells

International Journal of Cancer

Volumn 136, Issue 9, 2015, Pages 2078-2090

  Veigel, Daniel ^a   Wagner, Renate ^a   Stübiger, Gerald ^a   Wuczkowski, Michael ^a   Filipits, Martin ^a,b   Horvat, Reinhard ^a   Benhamu, Bellinda ^c   López Rodriguez, Maria Luz ^c   Leisser, Asha ^a,d   Valent, Peter ^a,d   Grusch, Michael ^a,b   Hegardt, Fausto G ^e,f   Garcia, Jordi ^e,f   Serra, Dolors ^e,f   Auersperg, Nelly ^g   Colomer, Ramón ^h,i   Grunt, Thomas W ^a,d  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^d LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^e UNIVERSITY OF BARCELONA   (Spain)

^f Instituto de Salud Carlos III   (Spain)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^h HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

ⁱ Centro Nacional de Investigaciones Oncológicas   (Spain)

Author keywords

Fallopian tube secretory epithelial cells; Fatty acid synthase; Ovarian cancer; Ovarian surface epithelial cells; Senescence

Indexed keywords

BETA GALACTOSIDASE; BIOLOGICAL MARKER; C75; FATTY ACID SYNTHASE; FATTY ACID SYNTHASE INHIBITOR; G28UCM; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; FASN PROTEIN, HUMAN; TUMOR MARKER;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CANCER STEM CELL; CELL AGING; CELL IMMORTALIZATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; LIPID COMPOSITION; LIPOGENESIS; M PHASE CELL CYCLE CHECKPOINT; OVARIAN CANCER CELL LINE; OVARY CANCER; OVIDUCT; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THIN LAYER CHROMATOGRAPHY; CELL CYCLE; CELL LINE; DRUG EFFECTS; EPITHELIUM CELL; GENETICS; OVARIAN NEOPLASMS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; EPITHELIAL CELLS; FATTY ACID SYNTHASE, TYPE I; FEMALE; HUMANS; OVARIAN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84923166248     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29261     Document Type: Article

References (42)

1. Aunoble B, Sanches R, Didier E, et al. Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer (review). Int J Oncol 2000;16: 567-76.
2. Reibenwein J, Krainer M. Targeting signaling pathways in ovarian cancer. Expert Opin Ther Targets 2008;12: 353-65.
3. Wise DR, Thompson CB. Glutamine addiction: A new therapeutic target in cancer. Trends Biochem Sci 2010;35: 427-33.
4. Parks SK, Chiche J, Pouyssegur J. Disrupting proton dynamics and energy metabolism for cancer therapy. Nat Rev Cancer 2013;13: 611-23.
5. Bensinger SJ, Christofk HR. New aspects of the Warburg effect in cancer cell biology. Semin Cell Dev Biol 2012;23: 352-61.
6. Gordan JD, Thompson CB, Simon MC. HIF and c-Myc: Sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell 2007; 12: 108-13.
7. Osthus RC, Shim H, Kim S, et al. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem 2000;275: 21797-800.
8. Lopez-Lazaro M. The Warburg effect: Why and how do cancer cells activate glycolysis in the presence of oxygen? Anticancer Agents Med Chem 2008;8: 305-12.
9. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 2007;7: 763-77.
10. Jump DB. Mammalian fatty acid elongases. Methods Mol Biol 2009;579: 375-89.
11. Uddin S, Jehan Z, Ahmed M, et al. Overexpression of fatty acid synthase in Middle Eastern epithelial ovarian carcinoma activates AKT and its inhibition potentiates cisplatin-induced apoptosis. Mol Med 2011;17: 635-45.
12. Agostini M, Almeida LY, Bastos DC, et al. The fatty acid synthase inhibitor orlistat reduces the growth and metastasis of orthotopic tongue oral squamous cell carcinomas. Mol Cancer Ther 2014;13: 585-95.
13. Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis 2013;4: E532.
14. Maeda M, Scaglia N, Igal RA. Regulation of fatty acid synthesis and Delta9-desaturation in senescence of human fibroblasts. Life Sci 2009;84: 119-24.
15. Menendez JA, Vellon L, Mehmi I, et al. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proc Natl Acad Sci USA 2004;101: 10715-20.
16. Grunt TW, Wagner R, Grusch M, et al. Interaction between fatty acid synthase-And ErbBsystems in ovarian cancer cells. Biochem Biophys Res Commun 2009;385: 454-9.
17. Jin Q, Yuan LX, Boulbes D, et al. Fatty acid synthase phosphorylation: A novel therapeutic target in HER2-overexpressing breast cancer cells. Breast Cancer Res 2010;12: R96.
18. Flavin R, Peluso S, Nguyen PL, et al. Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol 2010;6: 551-62.
19. Grunt TW, Oeller H, Somay C, et al. Different propensity for spontaneous differentiation of cell clones isolated from the human ovarian surface epithelial cell line HOC-7. Differentiation 1993; 53: 45-50.
20. Karst AM, Levanon K, Drapkin R. Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. Proc Natl Acad Sci USA 2011; 108: 7547-52.
21. Li P, Maines-Bandiera S, Kuo WL, et al. Multiple roles of the candidate oncogene ZNF217 in ovarian epithelial neoplastic progression. Int J Cancer 2007;120: 1863-73.
22. Makowski K, Mera P, Paredes D, et al. Differential pharmacologic properties of the two C75 enantiomers: (1)-C75 is a strong anorectic drug; (-)-C75 has antitumor activity. Chirality 2013;25: 281-7.
23. Puig T, Turrado C, Benhamu B, et al. Novel inhibitors of fatty acid synthase with anticancer activity. Clin Cancer Res 2009;15: 7608-15.
24. Turrado C, Puig T, Garcia-Carceles J, et al. New synthetic inhibitors of fatty acid synthase with anticancer activity. J Med Chem 2012;55: 5013-23.
25. Liu H, Liu Y, Zhang JT. A new mechanism of drug resistance in breast cancer cells: Fatty acid synthase overexpression-mediated palmitate overproduction. Mol Cancer Ther 2008;7: 263-70.
26. Brünner-Kubath C, Shabbir W, Saferding V, et al. The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells. Breast Cancer Res Treat 2011;129: 387-400.
27. Grunt TW, Somay C, Pavelka M, et al. The effects of dimethyl sulfoxide and retinoic acid on the cell growth and the phenotype of ovarian cancer cells. J Cell Sci 1991;100: 657-66.
28. Grunt TW, Somay C, Oeller H, et al. Comparative analysis of the effects of dimethyl sulfoxide and retinoic acid on the antigenic pattern of human ovarian adenocarcinoma cells. J Cell Sci 1992;103: 501-9.
29. Grunt TW, Tomek K, Wagner R, et al. Upregulation of retinoic acid receptor-beta by the epidermal growth factor-receptor inhibitor PD153035 is not mediated by blockade of ErbB pathways. J Cell Physiol 2007;211: 803-15.
30. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957;226: 497-509.
31. Yao JK, Rastetter GM. Microanalysis of complex tissue lipids by high-performance thin-layer chromatography. Anal Biochem 1985;150: 111-16.
32. Kupke IR, Zeugner S. Quantitative highperformance thin-layer chromatography of lipids in plasma and liver homogenates after direct application of 0.5-microliter samples to the silicagel layer. J Chromatogr 1978;146: 261-71.
33. White T, Bursten S, Federighi D, et al. High-resolution separation and quantification of neutral lipid and phospholipid species in mammalian cells and sera by multi-one-dimensional thinlayer chromatography. Anal Biochem 1998;258: 109-17.
34. Auersperg N. The origin of ovarian cancers-hypotheses and controversies. Front Biosci (Schol Ed) 2013;5: 709-19.
35. Auersperg N. Ovarian surface epithelium as a source of ovarian cancers: Unwarranted speculation or evidence-based hypothesis? Gynecol Oncol 2013;130: 246-51.
36. Wang HQ, Altomare DA, Skele KL, et al. Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells. Oncogene 2005;24: 3574-82.
37. Tomek K, Wagner R, Varga F, et al. Blockade of fatty acid synthase induces ubiquitination and degradation of phosphoinositide-3-kinase signaling proteins in ovarian cancer. Mol Cancer Res 2011;9: 1767-79.
38. Grunt TW, Dittrich E, Somay C, et al. Separation of clonogenic and differentiated cell phenotypes of ovarian cancer cells (HOC-7) by discontinuous density gradient centrifugation. Cancer Lett 1991; 58: 7-16.
39. Hopperton KE, Duncan RE, Bazinet RP, et al. Fatty acid synthase plays a role in cancer metabolism beyond providing fatty acids for phospholipid synthesis or sustaining elevations in glycolytic activity. Exp Cell Res 2014;320: 302-10.
40. Seidenfeld J, Marton LJ. Effects of DL-Alphamethylornithine on proliferation and polyamine content of 9L rat brain tumor cells. Cancer Res 1980;40: 1961-6.
41. Harada JJ, Morris DR. Cell cycle parameters of Chinese hamster ovary cells during exponential, polyamine-limited growth. Mol Cell Biol 1981;1: 594-9.
42. Corney DC, Flesken-Nikitin A, Choi J, et al. Role of p53 and Rb in ovarian cancer. Adv Exp Med Biol 2008;622: 99-117.